Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04265729
Other study ID # MPR18TA23134
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 2020
Est. completion date March 2022

Study information

Verified date February 2020
Source Nutricia Research
Contact Danone Nutricia Research
Phone +31 30 295000
Email register.clinicalresearchnutricia@danone.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Infants and young children up to 10 years of age with a complex condition involving the gastrointestinal tract are at risk of poor nutritional status, including faltering growth. Due to the complex condition, standard nutrition is often not tolerated and causes gastrointestinal symptoms.

Formulas in which protein is replaced by its smallest elements, amino acids are easier for the body to digest and absorb. These formulas might be tolerated better and reduce gastrointestinal symptoms in infants and young children with complex conditions.

The objectives of the present, exploratory study are to gain clinical evidence related to the nutritional status and gastrointestinal tolerance in infants and young children with complex conditions receiving Neocate as their primary source of nutrition. Additional objectives are to describe the nutritional and pharmacological management of these infants and young children. Study duration for each participant will be 52 weeks at maximum.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date March 2022
Est. primary completion date July 2021
Accepts healthy volunteers No
Gender All
Age group N/A to 10 Years
Eligibility Inclusion Criteria:

- Infants and young children aged from 0 up to and including 10 years of age.

- Severe impairment of at least 1 organ system

- Impairment of the gastrointestinal tract, i.e. gastrointestinal disease, congenital abnormality, surgical resection, or gastrointestinal dysfunction (including symptoms of gastrointestinal dysmotility or malabsorption).

- Receiving at least 75% of their energy intake from Neocate (Neocate Infant or Junior powdered (marketed) product) at the time of study entry (V1).

- Expected to receive at least 75% of their energy intake from the study product for at least 4 weeks from study entry (V1).

- Written informed consent provided by parents/guardians and assent by the child, if applicable, according to local law.

Exclusion Criteria:

- Infants born with a gestational age <37 weeks that are <40 weeks corrected age at the time of study entry (V1).

- Infants or children with endoscopically confirmed eosinophilic oesophagitis and prescribed an amino acid-based formula only for the management of the eosinophilic oesophagitis.

- Infants or children with a medical diagnosis that includes only (suspected) cow's milk allergy and/or multiple food allergy.

- Infants or children with renal dysfunction, e.g. acute or chronic kidney failure or kidney cancer.

- Infants or children with thyroid disorder or parathyroid disorder.

- Expected to receive parenteral nutrition during intervention from study entry (V1).

- Participation in any other studies involving investigational or marketed products concomitantly or within 1 month prior to study entry (V1).

- Investigator's uncertainty about the willingness or ability of the parents/guardians to comply with the protocol requirements.

Study Design


Related Conditions & MeSH terms

  • Complex Conditions, Including Impairment of the GI Tract
  • Disease

Intervention

Dietary Supplement:
Neocate Infant and Junior marketed products
use of Neocate Infant and Junior marketed products

Locations

Country Name City State
Germany Dr. von Haunersches LKinderspital Munich
United Kingdom Great Ormond Street Hospital London
United States GI Care for Kids Atlanta Georgia
United States Prisma Health - Upstate Greenville South Carolina

Sponsors (1)

Lead Sponsor Collaborator
Nutricia Research

Countries where clinical trial is conducted

United States,  Germany,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Exploratory: Weight Weight [in g/kg] 0 weeks
Primary Exploratory: Weight Weight [in g/kg] 4 weeks
Primary Exploratory: Weight Weight [in g/kg] 16 weeks
Primary Exploratory: Weight Weight [in g/kg] 52 weeks
Primary Exploratory: Length Length/height [in cm] 0 weeks
Primary Exploratory: Length Length/height [in cm] 4 weeks
Primary Exploratory: Length Length/height [in cm] 16 weeks
Primary Exploratory: Length Length/height [in cm] 52 weeks
Primary Exploratory: head circumference head circumference (for children <2 years of age) [in cm] 0 weeks
Primary Exploratory: head circumference head circumference (for children <2 years of age) [in cm] 4 weeks
Primary Exploratory: head circumference head circumference (for children <2 years of age) [in cm] 16 weeks
Primary Exploratory: head circumference head circumference (for children <2 years of age) [in cm] 52 weeks
Primary Exploratory: Biochemical markers of nutritional status Macronutrient, micronutrient and mineral levels in blood [in a.o. mmol/L] 0 weeks
Primary Exploratory: Biochemical markers of nutritional status Macronutrient, micronutrient and mineral levels in blood [in a.o. mmol/L] 4 weeks
Primary Exploratory: Biochemical markers of nutritional status Macronutrient, micronutrient and mineral levels in blood [in a.o. mmol/L] 16 weeks
Primary Exploratory: Biochemical markers of nutritional status Macronutrient, micronutrient and mineral levels in blood [in a.o. mmol/L] 52 weeks
Primary Exploratory: Gastrointestinal tolerance GastrointestinaI symptoms [none/mild/moderate/severe] 0 weeks
Primary Exploratory: Gastrointestinal tolerance GastrointestinaI symptoms [none/mild/moderate/severe] 4 weeks
Primary Exploratory: Gastrointestinal tolerance GastrointestinaI symptoms [none/mild/moderate/severe] 16 weeks
Primary Exploratory: Gastrointestinal tolerance GastrointestinaI symptoms [none/mild/moderate/severe] 52 weeks
Primary Exploratory: Stool frequency number of stools per day 0 weeks
Primary Exploratory: Stool frequency number of stools per day 4 weeks
Primary Exploratory: Stool frequency number of stools per day 16 weeks
Primary Exploratory: Stool frequency number of stools per day 52 weeks
Primary Exploratory: Stool consistency parent reported stool consistency using stool scales (scale depending on diaper use or not) with categories within the range hard to watery 0 weeks
Primary Exploratory: Stool consistency parent reported stool consistency using stool scales (scale depending on diaper use or not) with categories within the range hard to watery 4 weeks
Primary Exploratory: Stool consistency parent reported stool consistency using stool scales (scale depending on diaper use or not) with categories within the range hard to watery 16 weeks
Primary Exploratory: Stool consistency parent reported stool consistency using stool scales (scale depending on diaper use or not) with categories within the range hard to watery 52 weeks
Primary Exploratory: Nutrient intake calculated energy, protein and micronutrient levels from parent diary [in a.o. mg/d] 0 weeks
Primary Exploratory: Nutrient intake calculated energy, protein and micronutrient levels from parent diary [in a.o. mg/d] 4 weeks
Primary Exploratory: Nutrient intake calculated energy, protein and micronutrient levels from parent diary [in a.o. mg/d] 16 weeks
Primary Exploratory: Nutrient intake calculated energy, protein and micronutrient levels from parent diary [in a.o. mg/d] 52 weeks